-
Recap: FDA Issues New Guidelines for Gene, Stem Cell Therapies
-
December 15: 2018 MIPS Reporting Webinar
-
AAPM&R Members in the News: November 2017
-
Charles A. Odonkor, MD, MA, Awarded 2017 President’s Citation Award
-
November Coding Q&A
-
Webinar on December 7: Employer Best Practices and Tips for Using the Job and Fellowship Board
-
Limbrel Capsules by Primus Pharmaceuticals: FDA Advisory - Linked to Potentially Life-Threatening Health Problems
-
Greenstone Issues Voluntary Nationwide Recall of Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP Due to Possible Sub Potent and Super Potent Tablets
-
AAPM&R Delegates Successfully Advocate for New Policy at AMA House of Delegates Meeting
-
15 Days Left to Submit an Informal Review Request - Review Your 2016 PQRS Feedback Report and 2016 Annual Quality and Resource Use Report Now
-
Update on Therapy Caps Legislation
-
Congratulations to Our 25-Year Members
-
Academy Endorses AMA Opioid Task Force Naloxone One-Pager
-
Compounded Glutamine, Arginine, and Carnitine Product for Injection by United Pharmacy: Compounding Risk Alert - FDA Investigates Two Adverse Events
-
Registry Participant Spotlight: Texas Pain Treatment Center
-
2017 AAPM&R Annual Business Meeting
-
Congratulations to the 2017 PM&R Journal Best Paper Award Recipients
-
CMS Finalizes Policies that Reduce Provider Burden, Lower Drug Prices
-
Experts Needed for Instructional Videos
-
Fresenius Kabi Issues Voluntary Nationwide Recall of Midazolam Injection, USP, 2 mg/2 mL Due to Reports of Blister Packages Containing Syringes of Ondansetron Injection, USP, 4 mg/2 mL